Готові списки джерел за темами / Parkison’s disease / Статті в журналах
Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Parkison’s disease.

Статті в журналах з теми "Parkison’s disease"

Автор: Grafiati
Опубліковано: 10 березня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-16 статей у журналах для дослідження на тему "Parkison’s disease".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Burke, Sarah Elizabeth, Immanuel B. H. Samuel, Qing Zhou, Benzi Kluger, Catherine Price, and Mingzhou Ding. "2210." Journal of Clinical and Translational Science 1, S1 (September 2017): 59. http://dx.doi.org/10.1017/cts.2017.210.

Повний текст джерела
Анотація:
OBJECTIVES/SPECIFIC AIMS: Identify objective neurological substrates of cognitive fatigue in Parkinson’s disease and in aging. METHODS/STUDY POPULATION: Structural and diffusion MRI. Behavioral assessments for aged adults and Parkinson’s disease. RESULTS/ANTICIPATED RESULTS: Gray and white matter deficits that correlate with deficits in the basal ganglia for fatigued Parkinson’s disease patients Versus anterior cingulate cortex in healthy aged adults with fatigue. DISCUSSION/SIGNIFICANCE OF IMPACT: Over 50% of patients with Parkison’s disease and 38% of healthy older adults suffer from cognitive fatigue. However, diagnostics are limited to subjective surveys and there are no treatments for either population. Therefore, objective measures are greatly needed for better diagnosis and development of treatment targets.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Chuma, Takayo. "Rehabilitation Medicine for Patients with Parkison's Disease." Japanese Journal of Rehabilitation Medicine 58, no. 3 (March 18, 2021): 303–11. http://dx.doi.org/10.2490/jjrmc.58.303.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Chuma, Takayo. "Rehabilitation Medicine for Patients with Parkison's Disease." Japanese Journal of Rehabilitation Medicine 56, no. 3 (March 18, 2019): 190–94. http://dx.doi.org/10.2490/jjrmc.56.190.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Juncos, Jorge, Lisa Aranitis, Charles Nemeroff, Dennis Sweitzer, and Paul Yeung. "QUETIAPINE IMPROVES PSYCHOTIC SYMPTOMS ASSOCIATED WITH PARKISON's DISEASE." American Journal of Geriatric Psychiatry 7 (September 1999): 45. http://dx.doi.org/10.1097/00019442-199911001-00132.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Marek, Kenneth, Danna Jennings, Gilles Tamagnan, and John Seibyl. "Biomarkers for Parkison's disease: Tools to assess Parkinson's disease onset and progression." Annals of Neurology 64, S2 (January 6, 2009): S111—S121. http://dx.doi.org/10.1002/ana.21602.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Hagenmüller, F., and M. Classen. "Motility of Oddi's Sphincter in Parkison's Disease, Progressive Systemic Sclerosis, and Achalasia." Endoscopy 20, S 1 (September 1988): 189–92. http://dx.doi.org/10.1055/s-2007-1018174.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Murdoch, B. "2.353 TREATMENT OF ARTICULATORY DYSFUNCTION IN PARKISON'S DISEASE USING REPETATIVE TRANSCRANIAL MAGNETIC STIMULATION." Parkinsonism & Related Disorders 18 (January 2012): S154. http://dx.doi.org/10.1016/s1353-8020(11)70675-7.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Siniscalchi, Antonio, Luca Gallelli, Nicola B. Mercuri, Guido Ferreri Ibbadu, and Giovambattista De Sarro. "Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa." Nutritional Neuroscience 9, no. 1-2 (February 2006): 11–16. http://dx.doi.org/10.1080/10284150600583446.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Kyuhou, Shin-ichi. "Preventive effects of phytoestrogens on the paraquat-induced toxicities in the cellular model of Parkison disease." Neuroscience Research 58 (January 2007): S234. http://dx.doi.org/10.1016/j.neures.2007.06.545.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Štuhec, Matej. "Memantine associated with parkisonism in a patient with Alzheimer's disease: A case study and the review of the literature." Anali PAZU 5, no. 1-2 (June 7, 2022): 6–9. http://dx.doi.org/10.18690/analipazu.5.1-2.6-9.2015.

Повний текст джерела
Анотація:
The positive effect of memantine on parkinsonism has been reported widely, but there have not been reports in the literature of parkinsonism, tremor and bradykinesis, induced by memantine, in an Alzheimer's patient, who did not have Parkinson's disease or a history of antipsychotic agents. In this case study, we report parkinsonism, tremor and night bradykinesis induced by memantine use (5 mg daily) in a 83-year-old Slovenian female patient. After memantine discontinuation, suggested by a clinical pharmacist specialist, and switching to donepezil 5 mg, the adverse drug reactions disappeared the next day. This case study may serve to help clinicians and clinical pharmacists distinguish memantine-induced parkinsonism from more serious conditions.
Стилі APA, Harvard, Vancouver, ISO та ін.
11

Gordon, Assaf, and M. V. Ragucci. "POSTER BOARD F8: MULTIPLE SCLEROSIS ACCOMPANIED BY PARKISON???S DISEASE: A CASE REPORT OF MANAGEMENT FOLLOWING HIP FRACTURE." American Journal of Physical Medicine & Rehabilitation 85, no. 3 (March 2006): 266–67. http://dx.doi.org/10.1097/00002060-200603000-00092.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
12

Timotijevic, L., M. Peacock, C. Hodgkins, and B. M. Egan. "Development of ethical governance framework for an mHealth platform for the management of Parkison’s." European Journal of Public Health 29, Supplement_4 (November 1, 2019). http://dx.doi.org/10.1093/eurpub/ckz185.281.

Повний текст джерела
Анотація:
Abstract Background The ubiquity of mobile devices promises to address the need for continuous management of chronic conditions at lower costs. Its rapid expansion, particularly in public health, is currently largely consumer-driven and lacking in acceptable frameworks for its wider adoption into the healthcare systems. The aim of this study is to identify the key parameters to consider in developing a governance framework for a Parkinson’s Disease Management MHealth platform. The Parkinson’s Disease Manager (PDM) system was developed to gather symptom information from patients with PD via wearable devices and a specially designed app and stored securely in a cloud, for use by clinicians, health researchers and policy makers. Methodology Twelve stakeholders were interviewed in the UK including clinicians, data managers, the public. First, the participants’ existing views about sharing personal and then specifically health data online were explored. Secondly, participants were introduced to PDM via a diagram and encouraged to explore the risks and benefits of the system with a minimum of guidance. Finally, they were asked what risks they thought might be posed by a series of specific scenarios presented through vignettes and how such issues might be addressed. Results Thematic analysis identified eight emerging themes which clustered around two overarching categories: 1. The key challenges of the system identified included: Establishing appropriate governance; Protecting the data; Ensuring sustainability; Building trust; 2. The proposed solutions included: Ethically informed governance; Embedded data custodians; Sustainable funding and engagement; Trust through transparency. Conclusions The patient’s heuristic assessment of risks and benefits is mediated by trust, which can be initially gained by association with individuals and organisations already deemed trustworthy and then consolidated and sustained through transparency and delivering on promises. Key messages The effective system design, must ensure that standards of transparency, data protection and informed consent are upheld if the coming eHealth revolution is ever to realise its true potential. The use of diagrams and vignettes to support qualitative interviews helped elucidate the importance of balancing protection, utility and sustainability to build and maintain trust.
Стилі APA, Harvard, Vancouver, ISO та ін.
13

Barbiera, Filippo, Giuseppe Cosentino, Francesco La Seta, Elena Vetrano, Bruno Murmura, Micol Avenali, Enrico Alfonsi, and Cristina Tassorelli. "A narrative review on the role and main findings of the Videofluoroscopic Study of Swallowing in Parkison’s disease." La radiologia medica, December 24, 2022. http://dx.doi.org/10.1007/s11547-022-01581-7.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
14

Хачатрян, Л. М., М. В. Погосян, M. A. Даниелян, З. А. Аветисян, А. Л. Минасян, А. Ю. Степанян та Дж. С. Саркисян. "Микроэлектрофизиологическое изучение соотношения возбудительных и тормозных синаптических процессов в кортиконигральной проекции к SNс на модели болезни Паркинсона". Medical Science of Armenia, 18 березня 2022, 83–90. http://dx.doi.org/10.54503/0514-7484-2022-61.1-3-83.

Повний текст джерела
Анотація:
In series experiments on 9 Albino rats (250 g) the comparative analyses of single neuron’s impulse activity of Substantia nigra compacta – SNc at high frequency stimulation (HFS) of the brain primary motor cortex (M1) in norm (107 neurons, n=4) and on the model of Parkison’s disease (PD) (105 neurons, n=5) has been conducted. Analyses of relative degree of depressor and excitatory effects frequency intensity on the base of spikes average frequency diagrams, represented as a disc diagram (in %) resulted in the following conclusions. In SNc neurons on the model of PD the poststimulus manifestations of depressor activity completely absent, but tetanic potentiation in both sequences 1,65- and 2,02-multiple exceeded of those in the norm. The comparative analyses of pre- and poststimulus frequency activity of SNc neurons on the model of PD, led to the conclusion that it is considerably higher in comparison with the norm. It has been revealed vulnerability of depressor poststimulus effects of SNc neurons, even their full absence, that in its turn, testifies about more involvement of SNc in PD.
Стилі APA, Harvard, Vancouver, ISO та ін.
15

Harfouche, A., A. Maciuk, P. Champy, G. Mazars, and B. Figadère. "Mucuna pruriens efficacy in Parkison disease: Systematic approach of clinically observed synergy." Planta Medica 78, no. 11 (July 2012). http://dx.doi.org/10.1055/s-0032-1320466.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
16

Regolanti, R., O. Bagni, P. Cannas, M. Raponi, A. Denaro, and N. Alessandri. "P409 CARDIAC SYMPATHOMIMETIC RESPONSE IN PARKINSON‘S PATIENTS VS HEALTHY ADULTS." European Heart Journal Supplements 24, Supplement_C (May 1, 2022). http://dx.doi.org/10.1093/eurheartj/suac012.395.

Повний текст джерела
Анотація:
Abstract In recent works, it has been observed that cardiac sympathetic innervation contributes to the hemodynamic adaptations of the cardiovascular system, in relation to numerous needs. Orimo et al, through the use of scintigraphy with MIBG, showed in Parkinson‘s patients a marked reduction in myocardial uptake of MIBG corresponding to cardiac sympathomimetic denervation, in relation to the severity of the disease. The aim of this work was to evaluate the morpho–functional variations of the heart at a programmed sympathomimetic stimulus (dopamine test), both in healthy patients and in those suffering from Parkinson‘s disease. Materials and Methods At the University Cardiology “La Sapienza” of Rome, Pontine Polo, 10 patients affected by PD (age 56±5,5, of which 6 M and 4 W) and 10 healthy (54±6,4, of which 6M,4W)were tested in the absence of cardiovascular FR; all patients performed: blood chemistry, ECG, chest x–ray, Eco–TSA, tilt test, echocardio– Dopamine (2D–stress) and MIBG Scintigraphy. 2D–stress echocardiogradia was assessed by t–student of F.acc + EF + left and right diastolic times + GLS + Tapse + PAPS at 10, 20.30.40 µ dopa and their correlation (r–pearson) in the two groups. Discussion The observation of the data in the two groups of patients, in the absence of ongoing and remote cardiological pathology, showed a behavior of the values in the range both in basal conditions and during dopa stimulation. The comparison of the two groups both basal and during progressive dose stimulation that a statistical difference (P < 0.05) is observed on both systolic and diastolic function. The comparison in the two groups in the different stimulus phases showed a parallel growth behavior but with a different speed (Dp / Dv). There is no single explanation for these results: certainly the central role is played by the poor representation of post–ganglionic nerve endings as well as by the significant reduction of cardiac adrenergic receptors in Parkison. Conclusion The small number of patients and the data observed, stimulates researchers to continue the study, to better understand which pathophysiological mechanisms underlie these observations and verify the presence of an inverse relationship between PD and all those cardiological pathologies caused by catecholaminergic hyperstimulus.
Стилі APA, Harvard, Vancouver, ISO та ін.
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії